Deutsche Bank (DE:DBKGn) analyst Pito Chickering maintained a Sell rating on Mednax (NYSE:MD) Inc on Friday, setting a price target of $24, which is approximately 26.36% below the present share price of $32.59.
Chickering expects Mednax Inc to post earnings per share (EPS) of $0.41 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Hold rating of shares in Mednax, with an average price target of $33.17.
The analysts price targets range from a high of $37 to a low of $24.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $472.96 million and a net profit of $52.67 million. The company's market cap is $2.81 billion.
According to TipRanks.com, Deutsche Bank analyst Pito Chickering is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.9% and a 70.69% success rate.
MEDNAX, Inc. provides physician services including newborn, anesthesia, maternal-fetal, tele radiology, pediatric cardiology and other pediatric subspecialty care. The company's solution include anesthesiology & pain management, prenatal, neonatal, pediatric, radiology, tele radiology, revenue cycle management and perioperative improvement consulting. MEDNAX was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.